Skip to main content

Cyfuse Biomedical K.K. (4892.T)

Japan Exchange Group Healthcare Drug Manufacturers - Specialty & GenericView data quality →
25.1Poor

ValueMarkers Composite Index

Top 0%#44,700 of 44,707
Overvalued

363% above intrinsic value ($1)

UndervaluedFair ValueOvervalued
Piotroski
4/9
Neutral
Beneish
-1.15
High Risk
Altman
1.12
Distress
DCF Value
$1
Overvalued
ROIC
-20.4%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Cyfuse Biomedical K.K. (4892.T) — VMCI valuation read

Composite valuation read on 4892.T: VMCI 25/100 against a Healthcare sector median of 50. The 25-point below-median print is the headline number for Cyfuse Biomedical K.K., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for 4892.T: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on 4892.T: 4892.T trades at 19.0x earnings, 6% above the Healthcare median of 18.0x; ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%); net debt to EBITDA of 0.8x leaves covenant headroom. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

4892.T rose 3.0% over the trailing 7 days, with a +1.0% read on a 30-day basis.

Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells. Cyfuse Biomedical K.K. was incorporated in 2010 and is based in Tokyo, Japan.

CEO: Shizuka Akieda21 employeesJPwww.cyfusebio.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 4892.T’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.